Anito-Cel Shows Durable Responses in Heavily Pretreated R/R Multiple Myeloma
New CAR T-cell therapy shows remarkable efficacy in treating relapsed multiple myeloma, achieving high response rates and minimal residual disease negativity.
Related Articles
Dr Voorhees Highlights Durability of Cilta-Cel in Myeloma
Peter M. Voorhees, MD, discusses the 5-year follow-up results from the CARTITUDE-1 trial, highlighting the long-term efficacy and durability of ciltacabtagene autoleucel in multiple myeloma.
Phase 1b Data Suggest Paxalisib Combo May Suppress CTCs in Metastatic TNBC
A promising clinical trial shows that a combination of paxalisib, pembrolizumab, and chemotherapy significantly reduces circulating tumor cells in metastatic triple-negative breast cancer.
Lower-Risk MDS Treatment Paradigms and Considerations for Transfusion and Pharmacologic Therapies
An expert discusses how the treatment landscape for lower-risk MDS has evolved with multiple new options including luspatercept, imetelstat, and lenalidomide based on specific patient…
Exploring MRD Testing and Data in Myeloma to Guide Treatment Decisions
During a live event, Jeffrey V. Matous, MD, discussed bispecific antibody treatment efficacy and safety in advanced multiple myeloma.
Dr Liu on Lurbinectedin: A New Era in SCLC Maintenance
New research reveals that combining lurbinectedin with atezolizumab significantly improves survival rates for patients with extensive-stage small cell lung cancer.
New Colorectal Cancer Therapies: Hope on the Horizon
Anita Turk, MD, discusses what she is most excited about regarding immunotherapy in the realm of colorectal cancer treatment.
Evolving Treatment Paradigms in Lower-Risk MDS: Current Therapeutic Options and Mechanistic Approaches
A panelist explains how the distinct mechanisms of erythropoiesis-stimulating agents (ESAs), luspatercept, and imetelstat offer tailored treatment options for anemia in lower-risk ESAs, enabling clinicians…
PD-L1 and HRD Correlation Shows Prognostic Value in Ovarian Cancer
New research reveals PD-L1 expression enhances survival in advanced ovarian cancer, linking it to homologous recombination deficiency and treatment personalization.
Dr Spigel Covers the AIM-HIGH Trial in Early NSCLC
David Spigel, MD, discusses the pivotal findings from the AIM-HIGH trial in early-stage non-squamous NSCLC.
FDA Draft Guidance Illuminates MDS Drug Development Pathways
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.